Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Oxurion NV ( (GB:0G99) ) just unveiled an update.
Oxurion NV has announced a capital increase of EUR 100,000 following the conversion of convertible bonds by Atlas Special Opportunities, LLC. This development is part of a larger EUR 20 million capital commitment that will help Oxurion focus on creating innovative therapies for preserving vision in the elderly, targeting a substantial market opportunity.
More about Oxurion NV
Oxurion, based in Leuven, Belgium, is a company focused on developing next-generation standard of care ophthalmic therapies for treating retinal diseases. The company targets significant market opportunities in the ophthalmology sector.
YTD Price Performance: 0%
Average Trading Volume: 3
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: €751.8K
For an in-depth examination of 0G99 stock, go to TipRanks’ Stock Analysis page.